MedTrace Logo

Diazoxide Choline Controlled-Release Tablet (DCCR) for Very High Triglycerides

NCT00973271 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2016-09-01

No results posted yet for this study

Summary

The hypothesis of this study is that DCCR is effective as both monotherapy and in combination with a statin in lowering triglycerides in subjects with very high triglycerides

Conditions

  • Hypertriglyceridemia

Interventions

DRUG

290 mg DCCR

290 mg diazoxide choline

DRUG

435 mg DCCR

435 mg diazoxide choline

DRUG

135 mg fenofibric acid

135 mg fenofibric acid

DRUG

Placebo

Placebos matching each of 2 doses of DCCR and 135 mg fenofibric acid

DRUG

atorvastatin

20 mg atorvastatin

Sponsors & Collaborators

  • Essentialis, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2011-11-30
Completion
2011-12-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00973271 on ClinicalTrials.gov